Physician profile
Michael Borts
NPI 1912991753
$17,288.45
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $5,209 · 2021: $3,629 · 2022: $5,153 · 2023: $2,630 · 2024: $39.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,300 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,300.00 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13,036.85 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $940.07 | 2020-2023 | Cuvitru, Hyqvia, Takhzyro |
| Astrazeneca Pharmaceuticals LP | $765.50 | 2019-2023 | Fasenra, Breztri, Tezspire |
| Csl Behring | $602.19 | 2019-2023 | Hizentra, Haegarda |
| Grifols USA, LLC | $306.69 | 2020-2023 | Xembify |
| Genzyme Corporation | $221.42 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $133.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.34 | 2019-2023 | |
| Shire North American Group INC | $127.08 | 2019 | |
| Pfizer INC. | $119.55 | 2022-2024 | |
| Genentech USA, INC. | $116.05 | 2019-2023 | Xolair |
| Pharming Healthcare, INC. | $99.11 | 2022-2023 | Ruconest |
| Octapharma USA, INC. | $97.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $78.23 | 2019-2022 | |
| Amgen INC. | $76.66 | 2022-2023 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $75.38 | 2021-2022 | |
| Kaleo, INC. | $74.10 | 2020-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.80 | 2019-2022 | |
| Horizon Therapeutics Plc | $62.88 | 2020-2022 | |
| Optinose US, INC. | $47.82 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $33.29 | 2022-2023 | Orladeyo |
| Covis Pharma Gmbh | $23.42 | 2023 | |
| Aimmune Therapeutics, INC. | $19.35 | 2022 | |
| Bio Products Laboratory USA, INC. | $18.05 | 2023 | Gammaplex, Coagadex |
| Hikma Pharmaceuticals USA | $17.37 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Borts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.